Company intelligence / Profile preview

Infinite

Ownership: Private
Development stage: Other

Overview

Infinite has developed a proprietary platform that integrates cellular computing with advanced diagnostic devices ("microscope-on-a-chip") to enable rapid and predictive assessment of long-term health risks. Their patented approach aims to revolutionize safety testing by providing earlier insights into potential chronic diseases using cutting-edge scientific knowledge about disease mechanisms. The company claims world-first integration of these concepts into modern systems for predictive diagnostics.

Therapeutic areas: OtherChronic DiseasesChronic Disease Management
Modalities: DeviceDiagnostic technologyPlatform technology
Industry: Pathology

Beyond the preview

Go deeper on Infinite.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Infinite.

Explore the full profile